Clinical characteristics and treatment outcomes of nonmetastatic pediatric rhabdomyosarcoma at Vietnam National Cancer Hospital
Main Article Content
Abstract
Rhabdomyosarcoma is the most common type among soft tissue malignant in children. This article reviews the clinical characteristics and treatment outcome of 36 children with nonmetastatic rhabdomyosarcoma at the Pediatric Department of Vietnam National Cancer Hospital from 2021 - 2024. In this study, the median age was 10.6 years old (ranging from 5.3 - 14.6 years old); male accounted for 66.7%. The most common tumor locations were at the head and neck (41.7%) and parameningeal site (19.4%). The study found that 36.1% cases had FOXO1 fusion; 44.4% had regional lymph node metastasis and the high and very high group accounted for 66.6%. In this study, 17 children (47.2%) underwent surgery first, with 9/17 children having the entire tumor removed; 84.2% of children responded well to the first 3 chemotherapy courses. At the end of the study, the 4 years Overall survival rate and disease-free survival rate were 64.9% and 32.9%, respectively. There was no statistically significant difference in survival rate with tumor characteristics and risk groups. Multimodal treatment according to risk groups in non-metastasis rhabdomyosarcoma brings significant results, but early diagnosis and approach to large tumors with biopsy and chemotherapy before surgery are needed.
Article Details
Keywords
Nonmetastasis rhabdomyosarcoma, Rhabdomyosarcoma, Vietnam National Cancer hospital
References
2. Ksontini FL. Non Metastatic Rhabdomyosarcoma in Children: Therapeutic Outcome and Prognostic Factors of a Single Institution Case Series. Journal of Cancer Science & therapy. 2021; 13:7.
3. Shern JF, Selfe J, Izquierdo E, et al. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. J Clin Oncol. 2021; 39(26): 2859-2871. doi:10.1200/JCO.20.03060.
4. Bisogno G, Minard-Colin V, Zanetti I, et al. Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. J Clin Oncol. 2023; 41(13): 2342-2349. doi:10.1200/JCO.22.02093.
5. Đỗ Cẩm Thanh, Đỗ Hùng Kiên, Hoàng Thu Trang, Trần Hải Nam, Hoàng Thị Thuỳ Linh, Lê Thị Thuỳ Dung. Mô hình bệnh tật và Kết quả điều trị tại khoa Nhi Bệnh viện K - cơ sở Tân Triều. TNU Journal of Science and Technology. 2024; 229(13): 244-251.
6. Nyeko R, Geriga F, Angom R, Kambugu JB, van Heerden J. Predictors of survival among children and adolescents with rhabdomyosarcoma treated in a single resource-limited centre - Uganda. BMC Cancer. 2025; 25: 1299. doi:10.1186/s12885-025-14735-3.
7. Cosci I, Del Fiore P, Mocellin S, Ferlin A. Gender Differences in Soft Tissue and Bone Sarcoma: A Narrative Review. Cancers (Basel). 2023; 16(1): 201. doi:10.3390/cancers16010201.
8. Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. Cancers (Basel). 2020; 12(7): 1758. doi:10.3390/cancers12071758.
9. Park M, Lee JA, Jin HY, et al. Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience. J Cancer Res Clin Oncol. 2022; 149(7): 3109-3119. doi:10.1007/s00432-022-04192-x.
10. Markiz SN, Khan S, Wagley ZB, et al. Rhabdomyosarcoma in children: Retrospective analysis from a single tertiary care center in Saudi Arabia. Cancer Rep (Hoboken). 2022; 6(1): e1683. doi:10.1002/cnr2.1683.
11. Mai VTP, Anh CTT, Khương TC. Chẩn đoán và điều trị sarcôm cơ vân ở trẻ em. Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế. 2013; (17): 333-338.
12. Nghiêm Ngọc Linh, Bùi Ngọc Lan. Nghiên cứu đặc điểm dịch tễ học lâm sàng và nhận xét kết quả điều trị Sarcom cơ vân trẻ em. Tạp chí Y học thực hành. 2018; (1080): 165-168.
13. Rees HD, Hills NK, Sabnis AJ, Tulpule AB, Shimotake TK, Goldsby RE. Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016. Cancer Rep (Hoboken). 2021; 5(5): e1503. doi:10.1002/cnr2.1503.
14. Preechawetchakul P, Sripornsawan P, Rajborirug S, Sangkhathat S, Sangsupavanich P, Chotsampancharoen T. Inferior Clinical Outcomes of Pediatric Rhabdomyosarcoma in Thailand: A 16-Year Experience in a Single Tertiary Institution. Asian Pac J Cancer Prev. 2022; 23(8): 2805-2811. doi:10.31557/APJCP.2022.23.8.2805.
15. Ramanathan S, Sisodiya S, Shetty O, et al. Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India. Ecancermedicalscience. 2023; 17: 1539. doi:10.3332/ecancer.2023.1539.
16. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in Childhood Rhabdomyosarcoma Incidence and Survival in the United States (1975-2005). Cancer. 2009; 115(18): 4218-4226. doi:10.1002/cncr.24465.
17. El-Badawy SA, El-Badawy SA. Treatment of non-metastatic rhabdomyosarcoma and other non rhabdomyosarcoma soft tissue malignant tumours of childood and adolesence. J Clin Oncol. 2005; 23(16_suppl):8557-8557. doi:10.1200/jco.2005.23.16_suppl.8557.